## BAX: Baxter International Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.3% below STRENGTH zone (3.0-6.0%); PEG 35.42 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($17.30)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 0, Bearish: 10)

**1. Levi & Korsinsky Notifies Baxter International, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – BAX**
- Source: GlobeNewswire | 20251204T211931 | Bearish | Relevance: 100%
- Levi & Korsinsky, LLP is notifying investors of Baxter International, Inc. (NYSE: BAX) about a class action lawsuit alleging securities fraud between February 23, 2022, and July 30, 2025. The lawsuit claims Baxter made false statements and/or concealed defects in its Novum LVP product, leading to patient harm. Investors have until December 15, 2025, to request appointment as lead plaintiff.

**2. Baxter International, Inc. (BAX) Investors: December 15, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser**
- Source: WGN Radio 720 | 20251204T130840 | Bearish | Relevance: 100%
- Lieff Cabraser Heimann & Bernstein, LLP reminds investors of Baxter International, Inc. (NYSE:BAX) who purchased stock between February 23, 2022, and July 30, 2025, about a securities class action lawsuit with a lead plaintiff deadline of December 15, 2025. The lawsuit alleges that Baxter made misleading statements and failed to disclose critical defects with its Novum LVP medical device, which led to malfunctions, serious injuries, and patient deaths. Following the disclosure of these issues and a temporary pause in shipments of the device, Baxter's stock price fell significantly.

**3. SueWallSt Podcast Explains Class Action Against Baxter International, Inc. (BAX)**
- Source: Fox 59 | 20251204T130755 | Bearish | Relevance: 100%
- Levi & Korsinsky, LLP has released a podcast detailing a class action securities lawsuit against Baxter International, Inc. (NYSE:BAX). The lawsuit alleges securities fraud between February 23, 2022, and July 30, 2025, claiming Baxter made false statements regarding defects in its Novum LVP product which caused patient harm. Investors who lost money are encouraged to contact Levi & Korsinsky for more information.

**4. BAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Baxter International, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!**
- Source: Fox 59 | 20251204T120851 | Bearish | Relevance: 100%
- Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Baxter International, Inc. (NYSE: BAX) on behalf of investors who purchased securities between February 23, 2023, and July 30, 2025. The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in its Novum LVP products that caused malfunctions, patient harm, and subsequent risks to sales. Investors who suffered losses have until December 15, 2025, to request to be appointed as lead plaintiff.

**5. Class Action Reminder from Pomerantz LLP for Shareholders of Baxter International, Inc. – BAX**
- Source: WGN Radio 720 | 20251204T120840 | Bearish | Relevance: 100%
- Pomerantz LLP has filed a class action lawsuit against Baxter International, Inc. (NYSE:BAX) following a 22.4% stock price drop on July 31, 2025. This decline occurred after Baxter announced a temporary pause in shipments and installations of its Novum LVP medical device due to an inability to commit to an exact resumption timing. Investors who purchased Baxter securities during the Class Period have until December 15, 2025, to seek appointment as Lead Plaintiff.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $15 | $19 | -21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.17M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.1% (+14.9%)
- Vanguard Group Inc: 12.2% (+0.5%)
- Dodge & Cox Inc.: 11.2% (+10.1%)
- Pzena Investment Man: 11.2% (+45.9%)
- State Street Corpora: 4.3% (+0.3%)

### Key Risks

1. Valuation stretched: PEG 35.4x requires aggressive growth execution.
2. Elevated short interest (9.8%): bears positioning against stock.
3. Long-term trend broken: trading 31.7% below SMA200.
4. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 35.42 signals overvaluation risk, limited margin of safety. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.0B |
| Beta | 0.61 |
| 52W Range | $17.40 - $37.74 |
| Short Interest | 9.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 35.42 |
| Forward P/E | 8.0 |
| Current P/E | 7.8 |
| YoY Growth | -2.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 0.1% to -2.3% (-2.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.3pp (needs >3.0% for momentum thesis). Below SMA200 (0.68x), long-term trend not supportive. RSI neutral at 42. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.30% (CS: 28) | Weak |
| RSI_14 | 42.4 | Neutral |
| MACD Histogram | 0.23 | Bullish |
| vs SMA20 | 1.007x | Above |
| vs SMA50 | 0.899x | Below |
| vs SMA200 | 0.683x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $18.48
- **Stop Loss:** $17.30 (6.4% risk)
- **Target:** $19.66 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 423
- **Position Value:** $7,817.04
- **Portfolio %:** 7.82%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-19 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.60 | $0.69 | +15.4% |
| 2025Q2 | $0.61 | $0.54 | -11.5% |
| 2025Q1 | $0.48 | $0.55 | +13.8% |
| 2024Q4 | $0.53 | $0.58 | +9.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*